Logo image
Back
Gastric per-oral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids
Journal article   Open access

Gastric per-oral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids

Maham Hayat, Abel Joseph, Yasi Xiao, Abdullah Abbasi, Saurabh Chandan, Sagar Pathak, Bani Fawwaz BahaAldeen, Aimen Farooq, Natalie Cosgrove, Deepanshu Jain, …
iGIE : innovation, investigation and insights, Vol.5(1), pp.13-20
03/01/2026
DOI: 10.1016/j.igie.2025.05.001
PMCID: PMC13064457
PMID: 41969774
url
https://doi.org/10.1016/j.igie.2025.05.001View
Published (Version of record) Open Access

Abstract

It has been estimated that nearly half of patients with gastroparesis use opioids long term, are unable to cease or wean opioid use, and continue to endorse debilitating symptoms. The aim of this study was to evaluate outcomes of gastric peroral endoscopic myotomy (G-POEM) as compassionate treatment in patients with gastroparesis who are unable to discontinue long-term opioid use. This was a multicenter retrospective analysis of prospective databases containing patients with gastroparesis taking opioids who underwent G-POEM between January 2021 and November 2024. Functional luminal imaging probe (FLIP) pyloric measurements were obtained pre- and post-G-POEM at follow-up. Clinical response to G-POEM was defined as improvement of ≥1 point on the Gastroparesis Cardinal Symptom Index. Thirty-eight patients with gastroparesis on opioids with a median follow-up of 6 months (range 3-18 months) underwent G-POEM during the study period. Technical success was 100%. Clinical success was achieved in 60.5% (23/38) of the patients. There were no differences in demographics, symptom duration, etiology of gastroparesis, baseline Gastroparesis Cardinal Symptom Index score, gastric emptying scintigraphy or daily morphine milligram equivalent between responders and nonresponders. When compared with nonresponders, patients who responded to G-POEM had a significantly lower FLIP baseline pyloric diameter (13.2 ± 3.4 mm2 vs 15.6 ± 2.7 mm2; P = .04) and distensibility index (4.8 ± 1.9 mm2/mm Hg vs 8.4 ± 4.6 mm2/mm Hg; P = .004). Clinical response was associated with improvement in FLIP pyloric diameter and distensibility index. This study suggests that G-POEM could be considered as a safe and effective compassionate treatment in select patients with gastroparesis who are taking opioids long term, particularly those with lower pyloric compliance on physiologic testing. Future studies are needed to corroborate these preliminary findings.
 G-POEM GCSI IQR GES DI FLIP

Details

Metrics

10 Record Views
Logo image